RastogiA. Sevelamer revisited: Pleiotropic effects on endothelial and cardiovascular risk factors in chronic kidney disease and end-stage renal disease. Ther Adv Cardiovasc Dis, 2013; 7(6):322–342; doi: 10.1177/1753944713513061
2.
ChenH, XieC-S, LiY-S, et al.Evaluation of the safety and efficacy of transarterial sevelamer embolization in a rabbit liver cancer model: A challenge on the size rule for vascular occlusion. Front Bioeng Biotechnol, 2022; 10:1058042; doi: 10.3389/fbioe.2022.1058042
3.
XuH, ZhouS, TangQ, et al.Cholesterol metabolism: New functions and therapeutic approaches in cancer. Biochim Biophys Acta, 2020; 1874(1):188394; doi: 10.1016/j.bbcan.2020.188394
4.
KhatibSA, WangXW. Proteomic heterogeneity reveals SOAT1 as a potential biomarker for hepatocellular carcinoma. Transl Gastroenterol Hepatol, 2019; 4:37; doi: 10.2103/7/tgh.2019.05.09
5.
WangZ, WangM, ZhangM, et al.High-affinity SOAT1 ligands remodeled cholesterol metabolism program to inhibit tumor growth. BMC Med, 2022; 20(1):292; doi: 10.1186/s12916-022-02436-8
6.
AngeleMK, WichmannMW, AyalaA, et al.Testosterone receptor blockade after hemorrhage in males: Restoration of the depressed immune functions and improved survival following subsequent sepsis. Arch Surg, 1997; 132(11):1207–1214; doi: 10.1001/archsurg.1997.01430350057010
7.
QuF, GuY, WangQ, et al.Metabolomic profiling to evaluate the efficacy of proxalutamide, a novel androgen receptor antagonist, in prostate cancer cells. Invest New Drugs, 2020; 38(5):1292–1302; doi: 10.1007/s10637-020-00901-w
8.
CadegianiFA, ZimermanRA, FonsecaDN, et al.Final results of a randomized, placebo-controlled, two-arm, parallel clinical trial of proxalutamide for hospitalized COVID-19 patients: A multiregional, joint analysis of the Proxa-Rescue AndroCoV trial. Cureus, 2021; 13(12):e20691; doi: 10.7759/cureus.20691
9.
BarmanM, KambleS, RoyS, et al.Antitheilerial activity of the anticancer histone deacetylase inhibitors. Front Microbiol, 2021; 12:759817; doi: 10.3389/fmicb.2021.759817
10.
BoatengAT, Abaidoo-MylesA, BonneyEY, et al.Isoform-selective versus nonselective histone deacetylase inhibitors in HIV latency reversal. AIDS Res Hum Retroviruses, 2022; 38(8):615–621; doi: 10.1089/aid.2021.0195
StojkovaP, SpidlovaP, StulikJ. Nucleoid-associated protein HU: A lilliputian in gene regulation of bacterial virulence. Front Cell Infect Microbiol, 2019; 9:159; doi: 10.3389/fcimb.2019.00159
13.
ZhangP, ZhaoX, WangY, et al.Bacteriophage protein Gp46 is a cross-species inhibitor of nucleoid-associated HU proteins. Proc Natl Acad Sci U S A, 2022; 119(9):e2116278119; doi: 10.1073/pnas.2116278119
14.
HallED, Von VoigtlanderPF. Facilitatory effects of piracetam on excitability of motor nerve terminals and neuromuscular transmission. Neuropharmacology, 1987; 26(11):1573–1579; doi: 10.1016/0028-3908(87)90003-7
15.
DezenaRMB, Antunes N deJ, CamposR, et al.Pharmacodynamic evaluation of L-carnitine and piracetam in muscle injury induced by the chronic use of simvastatin. Int J Clin Pharmacol Ther, 2020; 58(09):482–490; doi: 10.5414/CP203496
16.
LeisM, FlemingP. Prurigo nodularis: Review and emerging treatments. Skin Ther Lett, 2021; 26(3):5–8.
17.
AgrawalD, SardanaK, MathachanSR, et al.A prospective study examining the expression of STAT 1, 3, 6 in prurigo nodularis lesions with its immunopathogenic and therapeutic implications. J Cosmet Dermatol, 2022; 21(9):4009–4015; doi: 10.1111/jocd.14709
18.
LiuT, ChuY, WangY, et al.Successful treatment of prurigo nodularis with tofacitinib: The experience from a single center. Int J Dermatol, 2022; [Epub ahead of print]; doi: 10.1111/ijd.16568
19.
D'AngeloF, BaldelliV, HallidayN, et al.Identification of FDA-approved drugs as antivirulence agents targeting the pqs quorum-sensing system of Pseudomonas aeruginosa. Antimicrob Agents Chemother, 2018; 62(11):e01296-18; doi: 10.1128/AAC.01296-18
20.
WangM, ShimJS, LiR-J, et al.Identification of an old antibiotic clofoctol as a novel activator of unfolded protein response pathways and an inhibitor of prostate cancer. Br J Pharmacol, 2014; 171(19):4478–4489; doi: 10.1111/bph.12800
ChengAN, LoY-K, LinY-S, et al.Identification of Novel Cdc7 Kinase Inhibitors as Anti-Cancer Agents that Target the Interaction with Dbf4 by the Fragment Complementation and Drug Repositioning Approach. eBioMedicine, 2018; 36:241–251; doi: 10.1016/j.ebiom.2018.09.030
23.
BelouzardS, MachelartA, SencioV, et al.Clofoctol inhibits SARS-CoV-2 replication and reduces lung pathology in mice. PLoS Pathog, 2022; 18(5):e1010498; doi: 10.1371/journal.ppat.1010498
24.
ContestabileA, MagaraS, CanceddaL. The GABAergic hypothesis for cognitive disabilities in down syndrome. Front Cell Neurosci, 2017; 11; doi: 10.3389/fncel.2017.00054
25.
GoeldnerC, KishnaniPS, SkotkoBG, et al.A randomized, double-blind, placebo-controlled phase II trial to explore the effects of a GABAA-α5 NAM (basmisanil) on intellectual disability associated with Down syndrome. J Neurodev Disord, 2022; 14(1):10; doi: 10.1186/s11689-022-09418-0
26.
ValbuenaS, García Á, MazierW, et al.Unbalanced dendritic inhibition of CA1 neurons drives spatial-memory deficits in the Ts2Cje Down syndrome model. Nat Commun, 2019; 10(1):4991; doi: 10.1038/s41467-019-13004-9
27.
Van der VenLTM, PrinsenIM, JansenGH, et al.Growth of cultured human glioma tumour cells can be regulated with histamine and histamine antagonists. Br J Cancer, 1993; 68(3):475–483; doi: 10.1038/bjc.1993.373
28.
AmirianES, Marquez-DoD, BondyML, et al.Antihistamine use and immunoglobulin E levels in glioma risk and prognosis. Cancer Epidemiol, 2013; 37(6):908–912; doi: 10.1016/j.canep.2013.08.004
29.
PlatsidakiE, DessiniotiC. Recent advances in understanding Propionibacterium acnes (Cutibacterium acnes) in Acne. F1000Res, 2018; 7: doi: 10.1268/8/f1000research.15659.1
30.
Rokowska-WaluchA, PawlaczykM, CybulskiM, et al.Stressful events and serum concentration of substance P in acne patients. Ann Dermatol, 2016; 28(4):464–469; doi: 10.5021/ad.2016.28.4.464
31.
LeeWJ, JungHD, LeeHJ, et al.Influence of substance-P on cultured sebocytes. Arch Dermatol Res, 2008; 300(6):311–316; doi: 10.1007/s00403-008-0854-1
32.
BalwaniM. Erythropoietic protoporphyria and X-linked protoporphyria: Pathophysiology, genetics, clinical manifestations, and management. Mol Genet Metab, 2019; 128(3):298–303; doi: 10.1016/j.ymgme.2019.01.020
33.
HalloyF, IyerPS, GhidiniA, et al.Repurposing of glycine transport inhibitors for the treatment of erythropoietic protoporphyria. Cell Chem Biol, 2021; 28(8):1221–1234.e6; doi: 10.1016/j.chembiol.2021.02.021
34.
YangW, SoaresJ, GreningerP, et al.Genomics of Drug Sensitivity in Cancer (GDSC): A resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res, 2013; 41(D1):D955–D961; doi: 10.1093/nar/gks1111
35.
SabatinoL, VassalleC, SeppiaCD, et al.Deiodinases and the three types of thyroid hormone deiodination reactions. Endocrinol Metab, 2021; 36(5):952–964; doi: 10.3803/EnM.2021.1198
36.
MarsiliA, TangD, HarneyJW, et al.Type II iodothyronine deiodinase provides intracellular 3,5,3′-triiodothyronine to normal and regenerating mouse skeletal muscle. Am J Physiol Endocrinol Metab, 2011; 301(5):E818–E824; doi: 10.1152/ajpendo.00292.2011
37.
RoseneML, WittmannG, Arrojo e DrigoR, et al.Inhibition of the type 2 iodothyronine deiodinase underlies the elevated plasma TSH associated with amiodarone treatment. Endocrinology, 2010; 151(12):5961–5970; doi: 10.1210/en.2010-0553
38.
NaberKG, NiggemannH, SteinG, et al.Review of the literature and individual patients' data meta-analysis on efficacy and tolerance of nitroxoline in the treatment of uncomplicated urinary tract infections. BMC Infect Dis, 2014; 14(1):628; doi: 10.1186/s12879-014-0628-7
39.
AbouelhassanY, YangQ, YousafH, et al.Nitroxoline: A broad-spectrum biofilm-eradicating agent against pathogenic bacteria. Int J Antimicrob Agents, 2017; 49(2):247–251; doi: 10.1016/j.ijantimicag.2016.10.017
40.
ChangW-L, HsuL-C, LeuW-J, et al.Repurposing of nitroxoline as a potential anticancer agent against human prostate cancer – a crucial role on AMPK/mTOR signaling pathway and the interplay with Chk2 activation. Oncotarget, 2015; 6(37):39806–39820; doi: 10.1863/2/oncotarget.5655
41.
LinW, SunJ, SadahiraT, et al.Discovery and validation of nitroxoline as a novel STAT3 inhibitor in drug-resistant urothelial bladder cancer. Int J Biol Sci, 2021; 17(12):3255–3267; doi: 10.7150/ijbs.63125
42.
RenL, JiangM, XueD, et al.Nitroxoline suppresses metastasis in bladder cancer via EGR1/circNDRG1/miR-520h/smad7/EMT signaling pathway. Int J Biol Sci, 2022; 18(13):5207–5220; doi: 10.7150/ijbs.69373
43.
NagraniNS, BhawanJ. Histopathological variants of cutaneous neurofibroma: A compendious review. Dermatopathology, 2023; 10(1):1–19; doi: 10.3390/dermatopathology10010001
44.
RadomskaKJ, CoulpierF, GressetA, et al.Cellular origin, tumor progression, and pathogenic mechanisms of cutaneous neurofibromas revealed by mice with Nf1 knockout in boundary cap cells. Cancer Discov, 2019; 9(1):130–147; doi: 10.1158/2159-8290.CD-18-0156
45.
YangJ, ShamjiA, MatchacheepS, et al.Identification of a small-molecule inhibitor of class Ia PI3Ks with cell-based screening. Chem Biol, 2007; 14(4):371–377; doi: 10.1016/j.chembiol.2007.02.004
46.
SutinenA, NguyenGTT, RaasakkaA, et al.Structural insights into Charcot–Marie–Tooth disease-linked mutations in human GDAP1. FEBS Open Bio, 2022; 12(7):1306–1324; doi: 10.1002/2211-5463.13422
47.
NiemannA, HuberN, WagnerKM, et al.The Gdap1 knockout mouse mechanistically links redox control to Charcot–Marie–Tooth disease. Brain, 2014; 137(3):668–682; doi: 10.1093/brain/awt371
